US Patent 8962656 CCR2 antagonists
Patent 8962656 was granted and assigned to Boehringer Ingelheim on February, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+246 characters)
Article
Patent abstract
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (Ia) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
Edits on 21 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08962656 CCR2 antagonists US Patent 8962656 CCR2 antagonists
Infobox
Patent Number
0896265600
Patent Number
896265600
Edits on 21 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
089626560
Date of Patent
February 24, 2015
0Patent Application Number
137007520
Date Filed
May 26, 2011
0Official Website
Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
089626560
Date of Patent
February 24, 2015
0Patent Application Number
137007520
Date Filed
May 26, 2011
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 29 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08962656 CCR2 antagonists
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08962656
Date of patent
February 24, 2015
Patent application number
13700752
Date Filed
May 26, 2011
Patent primary examiner
Find more entities like US Patent 8962656 CCR2 antagonists
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.